肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Neurology：PD-1单抗对复发性高级别脑胶质瘤临床效果不佳

2018-09-03 zhangfan MedSci原创

复发性高级别脑胶质瘤PD-1HGG
关注

在本次真实世界研究中，未经严格筛选的复发性高级别脑胶质瘤接受PD-1单抗治疗后临床疗效不显著

近日研究人员考察了程序性细胞死亡受体1(PD-1)单抗Nivolumab或Pembrolizumab对复发性高级别脑胶质瘤(HGGs)患者的临床效果。

31名未经严格筛选的成年HGG患者参与本次单中心研究，接受Nivolumab(Opdivo)或Pembrolizumab(Keytruda)，部分患者先前接受过贝伐单抗治疗。

研究发现，接受首剂量PD-1单抗药物后，患者的平均无进展生存期(mPFS)为3.2个月，不同药物组患者之间mPFS差异不显著(nivolumab组mPFS 3.8个月 vs pembrolizumab 组mPFS 2.3个月)。先前接受过贝伐单抗治疗患者的mPFS为3.2个月，未接受贝伐单抗治疗者mPFS为3.7个月。患者接受首次PD-1治疗到死亡的平均时间为6.6个月。

在本次真实世界研究中，未经严格筛选的复发性高级别脑胶质瘤接受PD-1单抗治疗后临床疗效不显著。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000566, encodeId=278320005669b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 02 22:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909734, encodeId=bd011909e3484, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jun 15 01:18:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364848, encodeId=f2671364848f4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484488, encodeId=892f14844888f, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046613, encodeId=7f0f104661397, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Sep 03 13:18:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342420, encodeId=8164342420c0, content=单药效果不佳是肯定的，希望可以看到联合放疗或者CTL4的实验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Mon Sep 03 10:41:24 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342407, encodeId=7a6334240e9f, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:27:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342406, encodeId=394934240657, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:26:54 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-11-02 yinhl1978

    #Neurol#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2000566, encodeId=278320005669b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 02 22:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909734, encodeId=bd011909e3484, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jun 15 01:18:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364848, encodeId=f2671364848f4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484488, encodeId=892f14844888f, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046613, encodeId=7f0f104661397, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Sep 03 13:18:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342420, encodeId=8164342420c0, content=单药效果不佳是肯定的，希望可以看到联合放疗或者CTL4的实验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Mon Sep 03 10:41:24 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342407, encodeId=7a6334240e9f, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:27:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342406, encodeId=394934240657, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:26:54 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2019-06-15 hb2008ye

    #复发性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2000566, encodeId=278320005669b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 02 22:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909734, encodeId=bd011909e3484, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jun 15 01:18:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364848, encodeId=f2671364848f4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484488, encodeId=892f14844888f, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046613, encodeId=7f0f104661397, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Sep 03 13:18:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342420, encodeId=8164342420c0, content=单药效果不佳是肯定的，希望可以看到联合放疗或者CTL4的实验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Mon Sep 03 10:41:24 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342407, encodeId=7a6334240e9f, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:27:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342406, encodeId=394934240657, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:26:54 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-09-05 doctor-chen9582

    #PD-1单抗#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2000566, encodeId=278320005669b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 02 22:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909734, encodeId=bd011909e3484, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jun 15 01:18:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364848, encodeId=f2671364848f4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484488, encodeId=892f14844888f, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046613, encodeId=7f0f104661397, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Sep 03 13:18:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342420, encodeId=8164342420c0, content=单药效果不佳是肯定的，希望可以看到联合放疗或者CTL4的实验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Mon Sep 03 10:41:24 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342407, encodeId=7a6334240e9f, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:27:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342406, encodeId=394934240657, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:26:54 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-09-05 12498d2fm53(暂无昵称)

    #临床效果#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2000566, encodeId=278320005669b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 02 22:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909734, encodeId=bd011909e3484, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jun 15 01:18:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364848, encodeId=f2671364848f4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484488, encodeId=892f14844888f, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046613, encodeId=7f0f104661397, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Sep 03 13:18:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342420, encodeId=8164342420c0, content=单药效果不佳是肯定的，希望可以看到联合放疗或者CTL4的实验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Mon Sep 03 10:41:24 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342407, encodeId=7a6334240e9f, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:27:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342406, encodeId=394934240657, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:26:54 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-09-03 CHANGE

    疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2000566, encodeId=278320005669b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 02 22:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909734, encodeId=bd011909e3484, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jun 15 01:18:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364848, encodeId=f2671364848f4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484488, encodeId=892f14844888f, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046613, encodeId=7f0f104661397, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Sep 03 13:18:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342420, encodeId=8164342420c0, content=单药效果不佳是肯定的，希望可以看到联合放疗或者CTL4的实验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Mon Sep 03 10:41:24 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342407, encodeId=7a6334240e9f, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:27:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342406, encodeId=394934240657, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:26:54 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-09-03 asuraxia

    单药效果不佳是肯定的，希望可以看到联合放疗或者CTL4的实验。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2000566, encodeId=278320005669b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 02 22:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909734, encodeId=bd011909e3484, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jun 15 01:18:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364848, encodeId=f2671364848f4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484488, encodeId=892f14844888f, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046613, encodeId=7f0f104661397, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Sep 03 13:18:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342420, encodeId=8164342420c0, content=单药效果不佳是肯定的，希望可以看到联合放疗或者CTL4的实验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Mon Sep 03 10:41:24 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342407, encodeId=7a6334240e9f, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:27:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342406, encodeId=394934240657, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:26:54 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-09-03 青龙偃月

    优质资源，共同学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2000566, encodeId=278320005669b, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Fri Nov 02 22:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909734, encodeId=bd011909e3484, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Jun 15 01:18:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364848, encodeId=f2671364848f4, content=<a href='/topic/show?id=da511390508' target=_blank style='color:#2F92EE;'>#PD-1单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13905, encryptionId=da511390508, topicName=PD-1单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484488, encodeId=892f14844888f, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Wed Sep 05 01:18:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046613, encodeId=7f0f104661397, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Sep 03 13:18:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342420, encodeId=8164342420c0, content=单药效果不佳是肯定的，希望可以看到联合放疗或者CTL4的实验。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/31/88b7a0fe36b7bac9361f6feb3f050afa.jpg, createdBy=674d2404499, createdName=asuraxia, createdTime=Mon Sep 03 10:41:24 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342407, encodeId=7a6334240e9f, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:27:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=342406, encodeId=394934240657, content=优质资源，共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160905/IMG57CD39B82D12E7926.jpg, createdBy=ac2c1946830, createdName=青龙偃月, createdTime=Mon Sep 03 10:26:54 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
    2018-09-03 青龙偃月

    优质资源，共同学习

    0